What is the recommended first-line treatment for pulmonary Aspergillus infection in an otherwise healthy adult?

Recommended Treatment for Aspergillus Lung Infection

For an otherwise healthy adult with pulmonary Aspergillus infection, oral voriconazole or itraconazole are the preferred first-line antifungal agents, with treatment duration of at least 6 months for symptomatic chronic disease. 1

Treatment Algorithm by Clinical Presentation

Invasive Pulmonary Aspergillosis (IPA)

• First-line therapy: Voriconazole monotherapy remains the standard of care 2, 3
• Alternative consideration: The 2025 ATS guideline suggests that either monotherapy with a mold-active triazole OR combination therapy (triazole + echinocandin) are acceptable options, though the evidence was insufficient to favor one over the other 2
• Critical caveat: Recent 2025 data shows echinocandins as first-line monotherapy resulted in significantly higher 30-day mortality (63% vs 30%) compared to triazoles, even when switched to salvage therapy 4. Echinocandins should NOT be used as first-line monotherapy.

Chronic Cavitary Pulmonary Aspergillosis (CCPA)

Treatment decision tree:

• Asymptomatic patients without weight loss, fatigue, or declining lung function → Observe with follow-up every 3-6 months 1
• Symptomatic patients (pulmonary symptoms, weight loss, fatigue) OR progressive radiographic/functional decline → Treat with minimum 6 months antifungal therapy 1

Preferred oral agents (in order):

1. Voriconazole or itraconazole (strong recommendation, high-quality evidence) 1
2. Posaconazole - third-line for adverse events or clinical failure 1

For treatment failures or resistance:

• IV micafungin, caspofungin, or amphotericin B may be considered, though responses are variable 1
• Progressive disease may require long-term or lifelong therapy with continuous monitoring for toxicity and resistance 1

Single Aspergilloma

• Asymptomatic with stable cavity (6-24 months) → Observe 1
• Symptomatic (especially hemoptysis) → Surgical resection if no contraindications 1
• Perioperative antifungal prophylaxis (voriconazole or echinocandin) suggested only if moderate spillage risk 1

Important Clinical Considerations

Therapeutic drug monitoring (TDM): Voriconazole requires TDM with target trough concentrations typically 1.0-5.5 mg/L, though interpretation should integrate CYP2C19 polymorphisms, disease severity, and immune status 5

Emerging resistance: Susceptibility testing of Aspergillus fumigatus isolates is recommended, particularly given emerging azole resistance patterns 3

Combination therapy nuances: The 2025 ATS guideline notes combination therapy may be more appropriate in critically ill patients or when triazole resistance is suspected, particularly in patients with positive galactomannan assays 2. However, this recommendation derived exclusively from hematological malignancy/transplant populations, and applicability to otherwise healthy adults is unclear 2.

Common Pitfalls to Avoid

1. Do not use echinocandins as first-line monotherapy - associated with significantly worse survival outcomes 4
2. Do not treat asymptomatic CCPA - observation is appropriate unless progression occurs 1
3. Do not assume all Aspergillus lung disease requires treatment - distinguish between colonization and true infection
4. Do not neglect monitoring - prolonged therapy requires continuous assessment for hepatotoxicity, drug interactions, and resistance development 1, 5